AG˹ٷ

STOCK TITAN

[8-K] Amneal Pharmaceuticals, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Celularity Inc. (symbol: CELUW) filed a new Form D reporting a completed Rule 506(b) private placement. The company sold $1.035 million of equity, warrants and the underlying securities to 14 investors, with the first sale on 22 Jul 2025. The entire authorized amount has been placed, leaving $0 remaining; the offering will not last beyond one year and is unrelated to any merger or acquisition. No broker-dealers were engaged, so no sales commissions or finder’s fees were paid. The minimum investment was listed as $0, and the company states that none of the proceeds will be paid to executive officers, directors or promoters named in the filing. Celularity, incorporated in Delaware and operating from Florham Park, NJ, classified itself under the Biotechnology industry group but declined to disclose its revenue range.

Celularity Inc. (simbolo: CELUW) ha depositato un nuovo Modulo D riportando un collocamento privato completato secondo la Regola 506(b). La società ha venduto 1,035 milioni di dollari in azioni, warrant e titoli sottostanti a 14 investitori, con la prima vendita avvenuta il 22 luglio 2025. L'intero importo autorizzato è stato collocato, lasciando 0 dollari residui; l'offerta non durerà oltre un anno e non è collegata a fusioni o acquisizioni. Non sono stati coinvolti broker-dealer, quindi non sono state pagate commissioni di vendita o commissioni di ricerca. L'investimento minimo è stato indicato come 0 dollari e la società dichiara che nessuno dei proventi sarà destinato a dirigenti, amministratori o promotori menzionati nel deposito. Celularity, incorporata nel Delaware e con sede a Florham Park, NJ, si è classificata nel settore Biotecnologie ma ha rifiutato di comunicare la fascia di fatturato.

Celularity Inc. (símbolo: CELUW) presentó un nuevo Formulario D reportando una colocación privada completada bajo la Regla 506(b). La compañía vendió 1.035 millones de dólares en acciones, warrants y los valores subyacentes a 14 inversores, con la primera venta el 22 de julio de 2025. Se colocó la totalidad del monto autorizado, quedando 0 dólares restantes; la oferta no durará más de un año y no está relacionada con ninguna fusión o adquisición. No se contrataron corredores de bolsa, por lo que no se pagaron comisiones de venta ni honorarios de buscadores. La inversión mínima se estableció en 0 dólares y la compañía declara que ninguno de los ingresos será pagado a ejecutivos, directores o promotores mencionados en el reporte. Celularity, constituida en Delaware y con operaciones en Florham Park, NJ, se clasificó en el sector de dzٱ𳦲ԴDZDzí pero se negó a revelar su rango de ingresos.

Celularity Inc. (심볼: CELUW)� Rule 506(b)� 따른 완료� 사모 발행� 보고하는 새로� Form D� 제출했습니다. 사� 1,035� 달러 규모� 주식, 워런� � 기초 증권� 14명의 투자�에게 판매했으�, � 판매� 2025� 7� 22�� 이루어졌습니�. 승인� 전체 금액� 배정되어 잔여 금액은 0달러이며, � 공모� 1년을 넘기지 않을 예정이고 어떤 합병이나 인수와� 관련이 없습니다. 중개업자� 참여하지 않아 판매 수수료나 중개 수수료가 지급되지 않았습니�. 최소 투자 금액은 0달러� 명시되었으며, 사� 제출 서류� 명시� 임원, 이사 또는 홍보자에� 수익금이 지급되지 않을 �이라� 밝혔습니�. 델라웨어� 법인 설립� Celularity� 뉴저지 플로� 파크에서 운영되며, 생명공학 산업군으� 분류했으� 매출 범위� 공개하지 않았습니�.

Celularity Inc. (symbole : CELUW) a déposé un nouveau formulaire D rapportant un placement privé achevé selon la règle 506(b). La société a vendu 1,035 million de dollars d’actions, de bons de souscription et des titres sous-jacents à 14 investisseurs, la première vente ayant eu lieu le 22 juillet 2025. Le montant total autorisé a été placé, laissant 0 dollar restant ; l’offre ne durera pas plus d’un an et n’est liée à aucune fusion ou acquisition. Aucun courtier n’a été engagé, donc aucune commission de vente ni frais de recherche n’ont été payés. L’investissement minimum était de 0 dollar, et la société déclare qu�aucun produit ne sera versé aux dirigeants, administrateurs ou promoteurs nommés dans le dossier. Celularity, incorporée dans le Delaware et opérant depuis Florham Park, NJ, s’est classée dans le secteur de la biotechnologie mais a refusé de divulguer sa fourchette de revenus.

Celularity Inc. (Symbol: CELUW) hat ein neues Formular D eingereicht, das eine abgeschlossene Privatplatzierung gemäß Regel 506(b) meldet. Das Unternehmen verkaufte 1,035 Millionen US-Dollar an Aktien, Warrants und zugrunde liegenden Wertpapieren an 14 Investoren, wobei der erste Verkauf am 22. Juli 2025 stattfand. Der gesamte genehmigte Betrag wurde platziert, sodass 0 US-Dollar verbleiben; das Angebot wird nicht länger als ein Jahr dauern und steht in keinem Zusammenhang mit Fusionen oder Übernahmen. Es wurden keine Broker-Dealer beauftragt, daher wurden keine Verkaufsprovisionen oder Vermittlungsgebühren gezahlt. Die Mindestanlage wurde mit 0 US-Dollar angegeben, und das Unternehmen erklärt, dass keiner der Erlöse an Führungskräfte, Direktoren oder Förderer gezahlt wird, die in der Einreichung genannt sind. Celularity, im Bundesstaat Delaware gegründet und mit Sitz in Florham Park, NJ, klassifizierte sich in der Biotechnologie-Branche, lehnte jedoch die Offenlegung seiner Umsatzspanne ab.

Positive
  • $1.035 million in new capital has already been secured, improving cash resources.
  • No sales commissions or finder’s fees, meaning 100% of proceeds benefit the company.
  • No proceeds directed to insiders, aligning capital use with shareholder interests.
Negative
  • Equity and warrant issuance introduces potential dilution for existing shareholders.
  • Issuer declined to disclose revenue range, limiting financial transparency for investors.

Insights

TL;DR � Small private raise fully closed; neutral impact given size and absence of fees.

Capital & Structure: The $1.035 million raise modestly boosts cash while incurring no placement costs, maximizing net proceeds. Because securities include equity and warrants, future dilution is possible but manageable at this scale.
Governance: Proceeds earmarked away from insiders reduces conflict risk. Filing under Rule 506(b) confines purchasers to accredited investors, limiting disclosure obligations but also restricting liquidity.
Materiality: Relative to typical biotech funding needs, the amount is minor, so balance-sheet impact is limited. Overall, the event is routine and carries neutral valuation implications.

Celularity Inc. (simbolo: CELUW) ha depositato un nuovo Modulo D riportando un collocamento privato completato secondo la Regola 506(b). La società ha venduto 1,035 milioni di dollari in azioni, warrant e titoli sottostanti a 14 investitori, con la prima vendita avvenuta il 22 luglio 2025. L'intero importo autorizzato è stato collocato, lasciando 0 dollari residui; l'offerta non durerà oltre un anno e non è collegata a fusioni o acquisizioni. Non sono stati coinvolti broker-dealer, quindi non sono state pagate commissioni di vendita o commissioni di ricerca. L'investimento minimo è stato indicato come 0 dollari e la società dichiara che nessuno dei proventi sarà destinato a dirigenti, amministratori o promotori menzionati nel deposito. Celularity, incorporata nel Delaware e con sede a Florham Park, NJ, si è classificata nel settore Biotecnologie ma ha rifiutato di comunicare la fascia di fatturato.

Celularity Inc. (símbolo: CELUW) presentó un nuevo Formulario D reportando una colocación privada completada bajo la Regla 506(b). La compañía vendió 1.035 millones de dólares en acciones, warrants y los valores subyacentes a 14 inversores, con la primera venta el 22 de julio de 2025. Se colocó la totalidad del monto autorizado, quedando 0 dólares restantes; la oferta no durará más de un año y no está relacionada con ninguna fusión o adquisición. No se contrataron corredores de bolsa, por lo que no se pagaron comisiones de venta ni honorarios de buscadores. La inversión mínima se estableció en 0 dólares y la compañía declara que ninguno de los ingresos será pagado a ejecutivos, directores o promotores mencionados en el reporte. Celularity, constituida en Delaware y con operaciones en Florham Park, NJ, se clasificó en el sector de dzٱ𳦲ԴDZDzí pero se negó a revelar su rango de ingresos.

Celularity Inc. (심볼: CELUW)� Rule 506(b)� 따른 완료� 사모 발행� 보고하는 새로� Form D� 제출했습니다. 사� 1,035� 달러 규모� 주식, 워런� � 기초 증권� 14명의 투자�에게 판매했으�, � 판매� 2025� 7� 22�� 이루어졌습니�. 승인� 전체 금액� 배정되어 잔여 금액은 0달러이며, � 공모� 1년을 넘기지 않을 예정이고 어떤 합병이나 인수와� 관련이 없습니다. 중개업자� 참여하지 않아 판매 수수료나 중개 수수료가 지급되지 않았습니�. 최소 투자 금액은 0달러� 명시되었으며, 사� 제출 서류� 명시� 임원, 이사 또는 홍보자에� 수익금이 지급되지 않을 �이라� 밝혔습니�. 델라웨어� 법인 설립� Celularity� 뉴저지 플로� 파크에서 운영되며, 생명공학 산업군으� 분류했으� 매출 범위� 공개하지 않았습니�.

Celularity Inc. (symbole : CELUW) a déposé un nouveau formulaire D rapportant un placement privé achevé selon la règle 506(b). La société a vendu 1,035 million de dollars d’actions, de bons de souscription et des titres sous-jacents à 14 investisseurs, la première vente ayant eu lieu le 22 juillet 2025. Le montant total autorisé a été placé, laissant 0 dollar restant ; l’offre ne durera pas plus d’un an et n’est liée à aucune fusion ou acquisition. Aucun courtier n’a été engagé, donc aucune commission de vente ni frais de recherche n’ont été payés. L’investissement minimum était de 0 dollar, et la société déclare qu�aucun produit ne sera versé aux dirigeants, administrateurs ou promoteurs nommés dans le dossier. Celularity, incorporée dans le Delaware et opérant depuis Florham Park, NJ, s’est classée dans le secteur de la biotechnologie mais a refusé de divulguer sa fourchette de revenus.

Celularity Inc. (Symbol: CELUW) hat ein neues Formular D eingereicht, das eine abgeschlossene Privatplatzierung gemäß Regel 506(b) meldet. Das Unternehmen verkaufte 1,035 Millionen US-Dollar an Aktien, Warrants und zugrunde liegenden Wertpapieren an 14 Investoren, wobei der erste Verkauf am 22. Juli 2025 stattfand. Der gesamte genehmigte Betrag wurde platziert, sodass 0 US-Dollar verbleiben; das Angebot wird nicht länger als ein Jahr dauern und steht in keinem Zusammenhang mit Fusionen oder Übernahmen. Es wurden keine Broker-Dealer beauftragt, daher wurden keine Verkaufsprovisionen oder Vermittlungsgebühren gezahlt. Die Mindestanlage wurde mit 0 US-Dollar angegeben, und das Unternehmen erklärt, dass keiner der Erlöse an Führungskräfte, Direktoren oder Förderer gezahlt wird, die in der Einreichung genannt sind. Celularity, im Bundesstaat Delaware gegründet und mit Sitz in Florham Park, NJ, klassifizierte sich in der Biotechnologie-Branche, lehnte jedoch die Offenlegung seiner Umsatzspanne ab.

false000172312800017231282025-08-052025-08-05

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 5, 2025
AMNEAL PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3848593-4225266
(State or other jurisdiction
of incorporation)
(Commission File Number)(IRS Employer
Identification No.)
400 Crossing Blvd
Bridgewater, NJ 08807
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (908) 947-3120
N/A
(Former Name or Former Address, if Changed Since Last Report) 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: 
Title of each classTrading Symbol(s)Name of each exchange on which registered
Class A Common Stock, par value $0.01 per shareAMRXThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 2.02Results of Operations and Financial Condition.
On August 5, 2025, Amneal Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its results for the second quarter ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
The information in this report furnished pursuant to Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended (the "Securities Act"), if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.
Item 7.01Regulation FD Disclosure.
Amneal will host a conference call and live webcast at 8:30 am Eastern Time today, August 5, 2025, to discuss its results. The live webcast and presentation will be accessible through the Investor Relations section of the Company’s website at https://investors.amneal.com. To access the call through a conference line, dial (833) 470-1428 (in the U.S.) with access code 627786. A replay of the conference call will be posted shortly after the call. For a list of toll-free international numbers, visit this website: https://www.netroadshow.com/events/global-numbers?confId=79971.
The information in this report furnished pursuant to Item 7.01 shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this report.
Item 9.01Financial Statements and Exhibits.
(d)    Exhibits.
The following exhibits are furnished herewith:
Exhibit No.Description
99.1
Press release issued August 5, 2025.
104The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 5, 2025
AMNEAL PHARMACEUTICALS, INC.
By:/s/ Anastasios Konidaris
Name:Anastasios Konidaris
Title:Executive Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)


FAQ

How much capital did Celularity Inc. (CELUW) raise in the Form D offering?

The company sold $1.035 million of securities, with the entire amount already placed.

What type of securities were issued in Celularity’s private placement?

The filing lists equity, warrants or other rights, and the securities underlying those warrants.

Were any sales commissions or finder’s fees paid in this offering?

No. The Form D reports $0 in sales commissions and finder’s fees.

How many investors participated and when did the first sale occur?

A total of 14 accredited investors participated; the first sale was on 22 Jul 2025.

Will any of the proceeds be paid to Celularity executives or directors?

The company states that $0 of the proceeds will be paid to the officers, directors or promoters named in the filing.
Amneal Pharmaceuticals Inc

NASDAQ:AMRX

AMRX Rankings

AMRX Latest News

AMRX Latest SEC Filings

AMRX Stock Data

2.45B
154.81M
46.75%
43.79%
1.73%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
United States
Bridgewater